

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxylozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Oxfendazole / Oxylozanide Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Liver, Testis, Brain)
repeated exposure

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Signal word	:	Danger
Hazard statements	:	H360FD May damage fertility. May damage the unborn child. H371 May cause damage to organs (Central nervous system) if swallowed. H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure. H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements	:	<p>Prevention: P203 Obtain, read and follow all safety instructions before use. P260 Do not breathe dust. P264 Wash hands thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.</p> <p>Response: P308 + P316 IF exposed or concerned: Get emergency medical help immediately. P391 Collect spillage.</p> <p>Storage: P405 Store locked up.</p> <p>Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.</p>

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
oxclozanide	2277-92-1	>= 30 - < 50
oxfendazole	53716-50-0	>= 20 - < 25
Starch, oxidized	65996-62-5	>= 10 - < 20
Magnesium stearate	557-04-0	>= 1 - < 5

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

In case of skin contact	Get medical attention. : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage fertility. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NO _x) Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers.

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxyclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Materials to avoid	Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. : Do not store with the following product types: Strong oxidizing agents
--------------------	--

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
oxyclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Starch, oxidized	65996-62-5	TWA (inhal- able dust)	0.5 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m ³	ACGIH
		TWA (Res- pirable par- ticulate mat- ter)	3 mg/m ³	ACGIH

Engineering measures

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks

Eye protection : Consider double gloving.
: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Hygiene measures

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Colour	: white to off-white, light cream, cream
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: Not applicable
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: Not applicable
Relative vapour density	: Not applicable
Relative density	: No data available
Density	: 0.88 g/cm ³

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 7942509-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available

10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	: Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	--

Components:

oxyclozanide:

Acute oral toxicity	: LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system
---------------------	--

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg
Application Route: Intravenous

oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
LD50 (Dog): 1,600 mg/kg
LD50 (sheep): 250 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

oxclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

oxclozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rabbit
Result : No eye irritation

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

oxyclozanide:

Exposure routes	:	Dermal
Remarks	:	Not classified due to lack of data.

Magnesium stearate:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

oxyclozanide:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
		Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxylozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Oral
Result: positive

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

oxylozanide:

Remarks : Not classified due to lack of data.

oxfendazole:

Species : Rat
Application Route : Oral
Exposure time : 1 Years
Symptoms : No adverse effects
Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Symptoms : No adverse effects
Target Organs : Liver

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

oxclozanide:

Effects on fertility

: Test Type: Two-generation reproduction toxicity study
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects, No effects on fertility

Effects on foetal development

: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 100 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 32 mg/kg body weight
Result: Fetotoxicity, Skeletal malformations

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility

: Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 17 mg/kg body weight
Target Organs: Testes
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.9 mg/kg body weight
Target Organs: Liver
Result: No effects on fertility

Test Type: Fertility
Species: Mouse
Application Route: Oral
Duration of Single Treatment: 1 Months
Fertility: NOAEL: 750 mg/kg body weight
Target Organs: Testes
Result: Effects on fertility

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: positive, Fetal effects

Test Type: Embryo-foetal development
Species: Rat
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: positive, Embryo-foetal toxicity

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 108 mg/kg body weight
Result: positive, Embryo-foetal toxicity, foetal abnormalities

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 0.625 mg/kg body weight

Reproductive toxicity - Assessment

: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 7942509-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

oxyclozanide:

Exposure routes : Oral
Target Organs : Central nervous system
Assessment : May cause damage to organs.

STOT - repeated exposure

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Components:

oxyclozanide:

Target Organs : Brain, Liver
Assessment : May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Exposure routes : Oral
Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

oxyclozanide:

Species : Rat
NOAEL : 9 mg/kg
LOAEL : 44.5 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Brain, Liver, spleen, Adrenal gland
Symptoms : Liver effects

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 7942509-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Species	:	Dog
NOAEL	:	5 mg/kg
LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver
Symptoms	:	blood effects, alteration in liver enzymes

oxfendazole:

Species	:	Rat
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Blood, Liver, Testis

Species	:	Rat
NOAEL	:	3.8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver, Testis

Species	:	Mouse
NOAEL	:	750 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Target Organs	:	Liver

Species	:	Mouse
NOAEL	:	37.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver

Species	:	Dog
NOAEL	:	6 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Remarks	:	No significant adverse effects were reported

Species	:	Dog
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Lymph nodes, thymus gland

Species	:	Dog
NOAEL	:	13.5 mg/kg
Application Route	:	Oral
Exposure time	:	12 Months
Target Organs	:	Liver

Starch, oxidized:

Species	:	Rat
---------	---	-----

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 7942509-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

||| NOAEL : 22,500 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Magnesium stearate:

||| Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

oxclozanide:

||| Not applicable

Experience with human exposure

Components:

oxclozanide:

||| Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

oxclozanide:

||| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

||| M-Factor (Acute aquatic toxicity) : 1

||| M-Factor (Chronic aquatic toxicity) : 1

oxfendazole:

||| Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l
Exposure time: 96 h

||| LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l
Exposure time: 96 h

||| Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.059 mg/l

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

aquatic invertebrates	Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (<i>Pseudokirchneriella subcapitata</i> (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (<i>Pseudokirchneriella subcapitata</i> (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 10
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 0.023 mg/l Exposure time: 21 d Species: <i>Daphnia magna</i> (Water flea) Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	: 1
Magnesium stearate:	
Toxicity to fish	: LC50 (<i>Leuciscus idus</i> (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (<i>Daphnia magna</i> (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	: EL50 (<i>Pseudokirchneriella subcapitata</i> (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility
	NOELR (<i>Pseudokirchneriella subcapitata</i> (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (<i>Pseudomonas putida</i>): > 100 mg/l Exposure time: 16 h

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

oxclozanide:

Stability in water : Hydrolysis: 50 %(156 d)
Method: OECD Test Guideline 111

oxfendazole:

Stability in water : Hydrolysis: < 5 %(4 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

oxclozanide:

Partition coefficient: n-octanol/water : log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n-octanol/water : log Pow: 1.95

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

oxclozanide:

Distribution among environmental compartments : log Koc: 4.83
Method: OECD Test Guideline 106

oxfendazole:

Distribution among environmental compartments : log Koc: 3.2

Other adverse effects

No data available

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, oxclozanide)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(oxfendazole, oxclozanide)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 956

Packing instruction (passenger aircraft) : 956

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, oxclozanide)

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F

Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 7942509-00009 Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development

SAFETY DATA SHEET

according to the Globally Harmonized System



Oxfendazole / Oxclozanide Formulation

Version
5.0

Revision Date:
14.04.2025

SDS Number:
7942509-00009

Date of last issue: 28.09.2024
Date of first issue: 19.03.2021

ment; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN